Summary:
- The RECOVER-VITAL clinical trial investigated whether a 15-day course of Paxlovid (nirmatrelvir/ritonavir) could effectively treat Long COVID symptoms compared to a placebo.
- The study concluded that the extended duration of Paxlovid provided no significant clinical benefit in reducing the severity of Long COVID symptoms among the trial participants.
- These findings are critical for the scientific community as they help narrow the scope of potential therapeutic interventions for post-acute sequelae of SARS-CoV-2 (PASC).